Mesothelioma prognosis is generally poor, with an overall five-year survival rate of about 15% for pleural mesothelioma, the most common form. However, that number is a broad average. Individual outlook varies significantly depending on where the cancer is located, what the tumor cells look like under a microscope, how far the disease has spread, and what treatments are possible.
Survival Rates by How Far It Has Spread
The American Cancer Society tracks pleural mesothelioma survival using data from 2015 to 2021, grouped by how far the cancer has spread at diagnosis. Localized disease, meaning the cancer is still confined to the lining where it started, carries a five-year relative survival rate of 23%. Regional disease, where it has spread to nearby lymph nodes or structures, drops to 15%. Distant disease, meaning it has reached organs or tissues far from the original site, has an 11% five-year survival rate.
These categories matter more than raw stage numbers for most patients, because they reflect what the cancer is actually doing in the body. Localized disease is caught less often because mesothelioma symptoms, like shortness of breath and chest pain, tend to appear only after the disease has already progressed. The gap between asbestos exposure and diagnosis is typically enormous: a median of about 23 years, with a range anywhere from 13 to 70 years. By the time symptoms develop, the cancer is often regional or distant.
How Cell Type Shapes the Outlook
One of the strongest predictors of survival is the type of cells that make up the tumor. Mesothelioma falls into three main categories based on how the cells look under a microscope.
The epithelioid type is the most common and the most favorable. Patients with pure epithelioid tumors have a median survival around 20 months. The sarcomatoid type is the most aggressive. Without treatment, patients with this subtype typically survive only five to six months. Biphasic tumors contain a mix of both cell types, and the ratio matters: when more than half of the tumor is epithelioid, median survival is roughly 12 months, but when the epithelioid component drops below 50%, it falls to about 7 months.
Pathologists determine the cell type from biopsy samples, and this information heavily influences treatment decisions. Sarcomatoid tumors respond less well to most therapies, which partly explains the survival gap.
Where the Cancer Starts Matters
Most mesothelioma develops in the lining of the lungs (pleural mesothelioma), but it can also arise in the lining of the abdomen (peritoneal), the heart (pericardial), or rarely the reproductive organs.
Peritoneal mesothelioma generally has a better outlook than pleural. At one year, about 50% of peritoneal patients are still alive compared to 40% of pleural patients. At five years, peritoneal survival is around 18% versus 5% for pleural. Part of this difference comes from treatment options: peritoneal mesothelioma can sometimes be treated with a combination of surgery and heated chemotherapy delivered directly into the abdomen, which isn’t possible for most pleural cases.
Pericardial mesothelioma is extremely rare and carries the worst prognosis of any form. In a population-based study from Italy’s National Mesothelioma Registry, the overall median survival was just 2.8 months. Older age at diagnosis, particularly over 75, and sarcomatoid cell type both worsened the outlook further.
Treatment Options and Their Impact
Without any treatment, median survival for pleural mesothelioma is roughly 7 to 9 months. Treatment can extend that to about 22 months in some cases, with the best outcomes seen in patients who can tolerate a multimodal approach combining surgery, chemotherapy, and radiation.
In studies of patients who completed full multimodal treatment, median survival reached 21 to 24 months. Not everyone is a candidate for this approach. It requires the cancer to be caught early enough for surgery to be feasible, and the patient needs to be healthy enough to recover from an extensive operation followed by additional therapy.
Immunotherapy has changed the treatment landscape in recent years. A major clinical trial comparing a combination immunotherapy regimen to standard chemotherapy found a median overall survival of 18.1 months with immunotherapy versus 14.1 months with chemotherapy. The benefit was particularly striking for non-epithelioid tumors: immunotherapy nearly doubled median survival in that group, from 8.8 months to 18.1 months. For epithelioid tumors, the difference was smaller (18.2 versus 16.7 months) and not statistically significant, though immunotherapy is still used as a first-line option for all subtypes.
What Affects an Individual’s Prognosis
Beyond cell type, stage, and location, several personal factors influence how long someone is likely to live with mesothelioma.
Age at diagnosis is one of the most consistent predictors. Younger patients tend to tolerate aggressive treatment better and generally survive longer. The average age at diagnosis is around 71 to 72, which limits treatment options for many patients. In pericardial mesothelioma specifically, being over 75 at diagnosis nearly tripled the risk of death compared to younger patients.
Gender has been studied extensively as a potential factor. Women have historically shown slightly better survival in some analyses, but a study focused specifically on non-epithelioid subtypes found no statistically significant survival difference between men and women after adjusting for other variables like age, cell type, and treatment. Any apparent advantage for women may reflect differences in the types of mesothelioma they develop or other overlapping factors rather than a direct biological effect.
Overall health and fitness play a practical role too. Patients who are physically active and have fewer other medical conditions are more likely to be candidates for surgery and aggressive treatment, which are the paths most associated with longer survival. Performance status, a clinical measure of how well someone can carry out daily activities, is one of the first things oncologists assess when planning treatment.
Why Early Detection Is Difficult
The long latency period between asbestos exposure and mesothelioma diagnosis is one of the defining challenges of the disease. The median gap is about 23 years, but it varies widely. People exposed at younger ages tend to have longer latency periods, while those exposed later in life or to heavier doses may develop the disease sooner. Women, on average, have latency periods about 29% longer than men.
This decades-long delay means many patients are elderly by the time they’re diagnosed, which limits their treatment options and contributes to the overall poor prognosis. There is currently no widely adopted screening test for mesothelioma, even in people with known asbestos exposure, so most cases are found only after symptoms appear and the disease is already advanced.